Nanobodies are small antibody fragments comprising the variable domains of the heavy-chain of conventional antibodies. Their small size allows for increased solubility, stability, and easy engineering into diagnostics, therapeutics, and research tools.
At the MHRA, we have identified a diverse panel of nanobodies with applications in the field of Influenza and SARS-CoV-2.
Explore the range of nanobodies available for commercial licensing.